Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if a new drug called ranibizumab is effective to
treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type
2 IMT). 10 patients will receive monthly injections of the drug into one eye over a period of
one year.